Search

1178 Result(s)
Sort by

Top-line Phase II Data for treatment of MASH

Top-line Phase II Data for treatment of MASH

Boehringer Ingelheim and Zealand Pharma announced top-line Phase II data for treatment of metabolic dysfuntion-associated steatohepatitis (MASH).
FDA approves additional formulation of biosimilar

FDA approves additional formulation of biosimilar

US FDA approves additional formulation of Cyltezo® (adalimumab-adbm). See Important Safety Information including Boxed Warning, Prescribing Information, Medication Guide and Instructions for Use.
Purpose Video IT

Purpose Video IT

Agustina Rojo, System Analyst in Buenos Aires, Argentina explains the many career opportunities Boehringer Ingelheim provides its employees.
Venu Thatikonda

Venu Thatikonda

An in-depth look into working life at Boehringer Ingelheim with Venu Thatikonda.